Briumvi (Ublituximab-xiiy) for Multiple Sclerosis

Overview
Briumvi is a prescription drug approved by the Food and Drug Administration (FDA) to treat adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. Briumvi is also referred to by its drug name, Ublituximab-xiiy.

Briumvi is a biologic immunomodulator, or in other words, a drug that modulates the immune system. Briumvi is a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Briumvi is believed to work by reducing the number of CD20-positive B cells, a type of immune system cell involved in nerve cell attacks.

How do I take it?
Briumvi is administered by intravenous infusion once every 24 weeks after initial loading doses.

Briumvi comes as a single-use vial.

Side effects
The FDA-approved label for Briumvi lists common side effects including infusion reactions and upper respiratory tract infections.

Rare but serious side effects listed for Briumvi include severe infusion reactions and increased risk for infections, including life-threatening or fatal infections.

For more details about this treatment, visit:

Briumvi - TG Therapeutics
https://briumvi.com/